Targeting persistence in tissue reservoirs represents a complex but essential step towards
achieving HIV cure. Combinatorial strategies, particularly during the early phases of …

Several studies have shown promise in many preclinical models of disease, including
simian immunodeficiency virus (SIV)/SHIV infection in nonhuman primates and HIV infection …

Human immunodeficiency virus type 1 (HIV-1)-specific broadly neutralizing monoclonal
antibodies (bNAbs) have to date shown transient viral suppression when administered as …

Despite antiretroviral therapy (ART), HIV persists in latently-infected cells (the HIV reservoir)
which decay slowly over time. Here, leveraging> 500 longitudinal samples from 67 people …

Following the emergence of the human immunodeficiency virus (HIV) pandemic, more than
2 decades of intense effort and investment was required to develop and implement …

A “blocked and locked” viral reservoir profile may constitute a structural virological correlate
of a functional cure of HIV-1 infection. Further research into the immunological mechanism …

Introduction The main barrier to finding a cure against HIV is the latent HIV reservoir, which
persists in people living with HIV (PLWH) despite antiretroviral treatment (ART). Here, we …

Although HIV infection can be managed with antiretroviral drugs, there is no cure and
therapy has to be taken for life. Recent successes in animal models with HIV-specific …

Background Analytical treatment interruption (ATI) is the gold standard in HIV research for
assessing the capability of new therapeutic strategies to control viremia without antiretroviral …

While no therapeutic strategy to date has succeeded in definitively inducing HIV control,
many studies have identified at least a small number of post-intervention controllers. The …